Todd Harris Sells 19,084 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris sold 19,084 shares of the firm’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $27.90, for a total transaction of $532,443.60. Following the completion of the transaction, the chief executive officer now directly owns 1,355,927 shares in the company, valued at approximately $37,830,363.30. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Todd Harris also recently made the following trade(s):

• On Thursday, October 17th, Todd Harris sold 15,394 shares of Tyra Biosciences stock. The shares were sold at an average price of $25.85, for a total transaction of $397,934.90.
• On Tuesday, October 15th, Todd Harris sold 10,035 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.31, for a total value of $243,950.85.
• On Monday, September 30th, Todd Harris sold 500 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.00, for a total value of $12,000.00.
• On Wednesday, September 25th, Todd Harris sold 600 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.01, for a total transaction of $14,406.00.
• On Monday, September 23rd, Todd Harris sold 10,092 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.13, for a total transaction of $243,519.96.
• On Thursday, September 19th, Todd Harris sold 5,698 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.31, for a total transaction of $138,518.38.

Tyra Biosciences Trading Up 0.3 %

TYRA stock opened at $28.24 on Thursday. The business’s fifty day moving average price is $22.75 and its 200 day moving average price is $19.73. Tyra Biosciences, Inc. has a 12-month low of $10.38 and a 12-month high of $28.99. The company has a market capitalization of $1.48 billion, a PE ratio of -16.81 and a beta of 1.01.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. Research analysts predict that Tyra Biosciences, Inc. will post -1.53 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on TYRA. Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and upped their price objective for the company from $22.00 to $31.00 in a report on Friday, October 18th. HC Wainwright upped their price target on Tyra Biosciences from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Piper Sandler began coverage on shares of Tyra Biosciences in a report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price objective on the stock. Oppenheimer upped their target price on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research report on Thursday, September 19th. Finally, Wedbush reissued an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a research note on Thursday, August 8th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $31.00.

Institutional Investors Weigh In On Tyra Biosciences

Several large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new position in shares of Tyra Biosciences in the third quarter worth $311,000. HighVista Strategies LLC acquired a new position in Tyra Biosciences during the 2nd quarter worth $257,000. Rhumbline Advisers increased its holdings in Tyra Biosciences by 12.3% during the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock worth $377,000 after purchasing an additional 2,574 shares during the period. Bank of New York Mellon Corp increased its holdings in Tyra Biosciences by 32.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock worth $929,000 after purchasing an additional 14,352 shares during the period. Finally, Oppenheimer & Co. Inc. purchased a new stake in Tyra Biosciences during the 1st quarter worth about $977,000. 84.14% of the stock is owned by hedge funds and other institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.